These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 23404727)

  • 1. The effect of different doses of subconjunctival bevacizumab injection on corneal neovascularization.
    Acar BT; Halili E; Acar S
    Int Ophthalmol; 2013 Oct; 33(5):507-13. PubMed ID: 23404727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of subconjunctival bevacizumab on corneal neovascularization: results of a prospective study.
    Benayoun Y; Adenis JP; Casse G; Forte R; Robert PY
    Cornea; 2012 Aug; 31(8):937-44. PubMed ID: 22357391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization.
    You IC; Kang IS; Lee SH; Yoon KC
    Acta Ophthalmol; 2009 Sep; 87(6):653-8. PubMed ID: 19021596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined use of subconjunctival and intracorneal bevacizumab injection for corneal neovascularization.
    Yeung SN; Lichtinger A; Kim P; Amiran MD; Slomovic AR
    Cornea; 2011 Oct; 30(10):1110-4. PubMed ID: 21673570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Corneal neovascularisation treatments compared: Subconjunctival bevacizumab injections and/or photodynamic therapy].
    Hamdan J; Boulze M; Aziz A; Alessi G; Hoffart L
    J Fr Ophtalmol; 2015 Dec; 38(10):924-33. PubMed ID: 26522892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subconjunctival bevacizumab injection for corneal neovascularization.
    Bahar I; Kaiserman I; McAllum P; Rootman D; Slomovic A
    Cornea; 2008 Feb; 27(2):142-7. PubMed ID: 18216566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Subconjunctival Injection of Bevacizumab in Regressing Corneal Neovascularisation.
    Shah SSA
    J Coll Physicians Surg Pak; 2019 May; 29(5):430-434. PubMed ID: 31036112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of photodynamic therapy with two different parameters combined with subconjunctival injection of bevacizumab for corneal neovascularization.
    Yin XF; Wu MH; Jin CJ; Zhou SY
    Photodiagnosis Photodyn Ther; 2024 Apr; 46():104067. PubMed ID: 38548042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subconjunctival bevacizumab for corneal neovascularization.
    Zaki AA; Farid SF
    Acta Ophthalmol; 2010 Dec; 88(8):868-71. PubMed ID: 19519730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ranibizumab injection for corneal neovascularization refractory to bevacizumab treatment.
    Ahn YJ; Hwang HB; Chung SK
    Korean J Ophthalmol; 2014 Apr; 28(2):177-80. PubMed ID: 24688262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium.
    Bahar I; Kaiserman I; McAllum P; Rootman D; Slomovic A
    Curr Eye Res; 2008 Jan; 33(1):23-8. PubMed ID: 18214740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Photodynamic therapy with verteporfin combined with subconjunctival injection of bevacizumab for corneal neovascularization.
    You IC; Im SK; Lee SH; Yoon KC
    Cornea; 2011 Jan; 30(1):30-3. PubMed ID: 20861729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Subconjunctival bevacizumab for corneal neovascularization].
    Gueudry J; Richez F; Tougeron-Brousseau B; Genevois O; Muraine M
    J Fr Ophtalmol; 2010 Nov; 33(9):630-6. PubMed ID: 21035899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical and subconjunctival bevacizumab for corneal neovascularization in an experimental rat model.
    Öner V; Küçükerdönmez C; Akova YA; Çolak A; Karalezli A
    Ophthalmic Res; 2012; 48(3):118-23. PubMed ID: 22538642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs.
    Hurmeric V; Mumcuoglu T; Erdurman C; Kurt B; Dagli O; Durukan AH
    Cornea; 2008 Apr; 27(3):357-62. PubMed ID: 18362668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinico-biochemical correlation of the effect of subconjunctival bevacizumab for corneal neovascularization.
    Agarwal S; Angayarkanni N; Iyer G; Srinivasan B; Natarajan R; Charola S; Arumugam S; Padmanabhan P
    Cornea; 2014 Oct; 33(10):1016-21. PubMed ID: 25090164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).
    Kim TI; Kim SW; Kim S; Kim T; Kim EK
    Cornea; 2008 Apr; 27(3):349-52. PubMed ID: 18362666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects of subconjunctival and topical anti-VEGF therapy (bevacizumab) on experimental corneal neovascularization.
    Ozdemir O; Altintas O; Altintas L; Ozkan B; Akdag C; Yüksel N
    Arq Bras Oftalmol; 2014 Aug; 77(4):209-13. PubMed ID: 25410169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subconjunctival bevacizumab for corneal neovascularization.
    Doctor PP; Bhat PV; Foster CS
    Cornea; 2008 Oct; 27(9):992-5. PubMed ID: 18812760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model.
    Avisar I; Weinberger D; Kremer I
    Curr Eye Res; 2010 Feb; 35(2):108-15. PubMed ID: 20136420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.